Food allergies are no longer being managed the way they were a decade ago, and the numbers tell that story clearly. The food allergy market stood at roughly USD 3,500 million in 2025 and is on track to climb to nearly USD 10,500 million by 2036 — a steady 9% CAGR across the 2026–2036 forecast window. That trajectory is being shaped across the seven major markets (the US, Germany, France, Italy, Spain, the UK, and Japan), where diagnosis, awareness, and treatment access are all advancing at different but meaningful paces.

What's driving this shift isn't just more patients being identified — it's a fundamental change in how the disease is being treated. The allergy treatment market as a whole is pivoting from a "just avoid the allergen" mindset toward therapies designed to actually retrain the immune system, and that pivot is visible everywhere in the current food allergy diagnosis treatment market landscape.

Why the Market Is Growing

A few forces stand out. First, sheer prevalence: the 7MM logged an estimated 61 million diagnosed cases in 2025 alone, with a slightly higher share among males (53%) than females (47%). Second, the science has matured — immunotherapies now show better safety and tolerability than older avoidance-based strategies, opening real commercial opportunity within the allergy immunotherapy market. Third, competition is heating up, with several late-stage candidates moving through trials and giving the space genuine momentum as part of the wider food allergy therapeutics category.

What the Epidemiology Data Shows

Zooming into the regional picture, Spain carries the heaviest diagnosed caseload among the EU4 and UK, with Germany close behind and France trailing at the bottom. Over in Japan, egg allergy tops the list of diagnosed food allergens, ahead of milk allergy, with fish allergy the least common — a detail that matters for anyone tracking the egg allergy market specifically. These region-by-region patterns are exactly what feed into a reliable food allergy epidemiology forecast, helping stakeholders anticipate where demand will grow fastest.

How the Disease Is Being Treated Today

Anaphylaxis remains the emergency to plan for, and epinephrine is still the only true first-line response — everything else, from antihistamines to corticosteroids, just manages symptoms around the edges. That reality continues to anchor the anaphylaxis treatment market.

On the approved-therapy side, three products currently define the field: omalizumab (XOLAIR), epinephrine nasal spray (NEFFY), and peanut allergen powder (PALFORZIA). XOLAIR, a Novartis and Roche collaboration, works by neutralizing free IgE before it can trigger a reaction — worth understanding if you're digging into XOLAIR MOA — and its 2024 food-allergy approval has made it a meaningful contributor to ongoing XOLAIR revenue growth. Meanwhile, PALFORZIA is on its way out: Stallergenes Greer is voluntarily pulling it from the market by July 31, 2026, a business decision unconnected to safety or efficacy, which is already reshaping expectations for the peanut allergy treatment market.

Beyond these, newer delivery routes — skin patches, sublingual films — are quietly building a safer profile for immune desensitization, adding fresh options to the hyposensitization therapy market.

Who's Building the Next Wave

Keep an eye on DBV Technologies' Viaskin Peanut Patch, Aravax's PVX108 (AVX-201), and Aquestive Therapeutics' ANAPHYLM sublingual film — three very different mechanisms, all chasing the same goal of safer, more durable protection. Not everything is going smoothly, though: Aquestive received a Complete Response Letter from the FDA in January 2026 on ANAPHYLM, a reminder of how closely regulators are scrutinizing this category. Anyone compiling a food allergy drug pipeline analysis report will want to watch how that plays out, alongside Novartis's plan to kick off a Phase III program for remibrutinib later in 2026.

Where the Regional Story Is Headed

The us food allergy diagnosis and treatment market remains the clear frontrunner, thanks to faster regulatory pathways, stronger awareness campaigns, and quicker uptake of new therapies. Within Europe, Germany leads on market share, followed by the UK, with France bringing up the rear — dynamics worth tracking separately across the germany food allergy diagnosis treatment market, uk food allergy diagnosis treatment market, france food allergy diagnosis treatment market, and spain food allergy diagnosis treatment market. Further east, the japan food allergy diagnosis treatment market is maturing steadily, and interest is building in the china food allergy diagnosis treatment market as testing infrastructure catches up.

Looking Ahead

As food allergen testing market tools get more precise and allergy diagnostic market access widens, the broader food allergy treatment market is set up for a long, steady climb through 2036 — with parallel gains likely across adjacent spaces like the allergic rhinitis market as diagnostic and treatment innovation cross-pollinates between allergic conditions.

Latest Reports Offered by Delveinsight

genital herpes market | glioma market | global kinase inhibitor in autoimmune diseases market | gpcr-targeting therapies market | graft versus host disease market | gvhd market | hairy cell leukemia market | hdac inhibitors market | her2+ gastric cancer market | her2-negative breast cancer market | hereditary angioedema market | hernia repair devices market | hidradenitis suppurativa market | hip replacement devices market | human papillomavirus hpv market | hyperkalemia market | hypogonadism market | hypoplastic left heart syndrome market | hypothalamic obesity market | immune checkpoints activators market | intracardiac echocardiography market | intracranial arterial diseases market | iron deficiency anemia market | ischemia reperfusion injury market | leukocyte adhesion deficiency market | lumbar disc disease market | 

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com